Finished, Finished

Postural Orthostatic Tachycardia Syndrome (POTS)

Location: Solmed Polyclinic (Zagreb)

Study Drug: Biological therapy that suppresses the excessive activity of B-lymphocytes that overly produce antibodies associated with this syndrome. The drug is already registered for the treatment of myasthenia gravis.

Main Inclusion Criteria: Patients over 18 years of age diagnosed with postural orthostatic tachycardia syndrome (POTS) after recovering from COVID-19.

Status: In preparation

Start of patient enrollment: August 2024.

Would you like to know more information on:

Postural Orthostatic Tachycardia Syndrome (POTS)

Contact us

What our patients say

Newsletter

Receive regular notifications about our activities and news in treatments.

Free examinations